Navigation Links
MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:3/4/2008

es affiliated with

Deerfield Management pursuant to the Keflex transaction, resulting from

MiddleBrook's consolidation of the two affiliates under Financial

Accounting Standards Board Interpretation No. 46 (revised 2003)

"Consolidation of Variable Interest Entities."

-- Net loss per share applicable to common stockholders for the fourth

quarter of 2007 was ($0.19), compared to a loss per common share of

($0.22) in the prior quarter and ($0.44) in the fourth quarter of 2006.

For the fiscal year of 2007, net loss per share applicable to common

stockholders was ($0.96), down from ($1.38) for the fiscal year of

2006.

Per share figures were computed on the basis of an average of 46.7

million shares outstanding in the fourth quarter of 2007, 46.7 million

shares outstanding in the third quarter of 2007, 31.5 million shares

outstanding in the fourth quarter of 2006; and 43.8 million shares

outstanding for the full year of 2007 and 30.5 million shares

outstanding for the full year of 2006.

-- Cash and marketable securities decreased by $4.0 million during the

fourth quarter. Changes were composed of $6.9 million of operating

losses, $4.9 million in loan payments, and $2.3 million for working

capital changes and other items; offset by $7.0 million raised from the

Deerfield Management Keflex transaction and $3.1 million for non-cash

expenses.

-- The Balance Sheet at the end of 2007 reflected $2.0 million of

unrestricted cash, cash equivalents and marketable securities, compared

to $15.4 million as of year-end 2006. Following the fourth quarter of

2007, MiddleBrook completed a private placement of common stock and

warrants resulting in the addition of $19.9 million of net proceeds to

the Company.

FINANCIAL GUIDANCE

Total r
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
3. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Victoria, Australia (PRWEB) September 02, 2014 ... provide a cure for chronic tinnitus are seeking support ... run on the Indiegogo platform ( http://igg.me/at/tinaway ), was ... to be a therapeutic ‘mHealth’ app and is based ... brainchild of a team of biomedical and software engineers, ...
(Date:8/31/2014)... -- Wockhardt Limited today announces a major boost to ... two of its drugs, WCK 771 and WCK 2349, ... from U.S. Food & Drug Administration (FDA).  QIDP status ... have a high degree of unmet need in their ... (a top U.S. government health and safety body).  QIDP ...
(Date:8/30/2014)... Dallas, TX (PRWEB) August 31, 2014 ... Industry is a professional and in-depth study on ... industry in Global and China. , The report ... definitions, applications and industry chain structure. Global market ... with a focus on history, developments, trends and ...
(Date:8/29/2014)... August 29, 2014 According to a new ... the global orthobiologics market was valued at USD 3,754.6 million ... USD 5,519.9million in 2019at a CAGR of 5.9% from 2013 ... years and above is afflicted by bone and joint disorders, ... year 2020. This has and will continue to increase the ...
Breaking Biology Technology:tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... , CAMBRIDGE, Mass., Aug. 11 Tolerx, ... therapies for immune-mediated diseases, today announced changes to the protocol for its ... of otelixizumab, a targeted T cell immunomodulator, in patients with new-onset autoimmune ... urable Response Therapy E valuation F or E arly ...
... WALTHAM, Mass., Aug. 11 Decision Resources, one of the world,s ... that the entry and uptake of premium-priced biologics will drive the ... $420 million in 2008 to nearly $2 billion in 2018. , ... Lupus Erythematosus finds that the primary drivers of market growth ...
... , , ... that BD Biosciences, a segment of BD (Becton, Dickinson and ... Pathway Navigation technologies into its new website. By leveraging ... its research customers to quickly and easily identify products and ...
Cached Biology Technology:Tolerx Announces Amendment to Phase 3 DEFEND Protocol 2Tolerx Announces Amendment to Phase 3 DEFEND Protocol 3Biologic Agents Will Drive the Systemic Lupus Erythematosus Drug Market to More Than Quadruple to Nearly $2 Billion in 2018 2Ingenuity's Technology Powers BD Cell Pathways Tool on New BD Biosciences Website 2
(Date:8/29/2014)... at UC Davis have made some surprising discoveries ... Studying simian immunodeficiency virus (SIV), the team found ... cells are early responders to viral invasion and ... a cytokine called interleukin-1 beta (IL-1β). , ... causes breakdown of the gut epithelium that provides ...
(Date:8/29/2014)... about what genetic changes transform wild animals into domesticated ... is a University of Montana assistant professor, has made ... of the brain and the nervous system were particularly ... 28 in Science and gives answers to ... ., The domestication of animals and plants, a prerequisite ...
(Date:8/29/2014)... understand how the repeated climatic shifts over the ... of genetic diversity, a team of researchers led ... Ana Carnaval developed a new biodiversity metric called ... which the genetic variation within species is restricted ... professor of biology, and 14 other researchers from ...
Breaking Biology News(10 mins):The early cost of HIV 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3CCNY team defines new biodiversity metric 2
... proteins are the bad guys that help bacterial pathogens do ... immune system. In essence, they knock down the front ... Now, researchers at the University of California, San Diego (UCSD) ... an effector protein called YpkA, one of several effectors of ...
... could soon be roaming our pastures, reports Cath O’Driscoll in ... in New Zealand have discovered that some cows have genes ... and plan to use this information to breed herds of ... plan to breed commercial herds producing milk with the unique ...
... H5N1 strain of avian influenza may hold the key to ... of researchers. In a study published today in the open ... antibodies taken from avian flu survivors in Vietnam can be ... virus in culture vitro and in mice. , The H5N1 ...
Cached Biology News:How plague-causing bacteria disarm host defense 2Skimmed milk -- Straight from the cow 2Avian influenza survivors' antibodies effective at neutralising H5N1 strain 2
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
Biology Products: